Why drug importation threatens patient safety

A closer look at why drug importation proposals put patient safety at risk.

Allyson Funk
Allyson FunkFebruary 28, 2017

Why drug importation threatens patient safety.

New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines.

Results-based contracts are an innovative approach to paying for medicines that often involve greater risk-sharing among payers and biopharmaceutical companies. They can also vary payment based on how well medicines work in different populations. As a result of these arrangements, payers can make a medicine more accessible to patients and biopharmaceutical companies agree to share the financial risk and be reimbursed based on how well medicines work for patients.  And the good news is biopharmaceutical companies and insurers are increasingly pursuing these types of arrangements.



Learn more at www.phrma.org/value-collaborative.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.